PCSK9 and metabolic syndrome: Although the lipid-lowering efficacy of PCSK9 inhibitors is supported by a wealth of evidence in dyslipidemia [16–18,21], the use of PCSK9 inhibitors remains low in the Arabian Gulf for patients with FH and those with highly elevated LDL-C levels.